The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "Sarilumab"

Search results for: Sarilumab

FDA Provides 2020 Rheumatology Drug Update

December 17, 2020 • By Susan Bernstein

Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.... [Read More]

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, FDA, meeting reports, U.S. Food and Drug Administration (FDA)

Tocilizumab Fails to Help COVID-19 Patients in Italian Study

June 23, 2020 • By Emilio Parodi & Carl O'Donnell

(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease… [Read More]

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, tocilizumab

Rheumatology in a COVID & Post-COVID World

May 11, 2020 • By Christopher Phillips, MD

Jane’s* hands and wrists had been swollen and painful for about eight weeks. Lab findings in the ambulatory consult that came to our office revealed a cyclic citrullinated peptide antibody count >250 u/mL. We all know where this story goes, including how important the early treatment window is. Our clinic reviews all consults and tries… [Read More]

Filed Under: Practice Management Tagged With: COVID-19, Dr. Chris Phillips, telehealth

Pharmacy Team Combats COVID-19 in NYC: Q&A with Mark J. Sinnett, PharmD, FASHP

May 1, 2020 • By Mary Choy, PharmD, BCGP, FASHP

The outbreak of the SARS-CoV-2 virus is disrupting patient care all over the world. In the U.S., many providers have had to adapt to new social distancing measures to care for patients, but struggles remain. Mark J. Sinnett, PharmD, FASHP, director of clinical and educational pharmacy services and director of the Center for Pharmacotherapy Research… [Read More]

Filed Under: Drug Updates, Professional Topics Tagged With: Association of Rheumatology Professionals (ARP), coronavirus, COVID-19, Hydroxychloroquine (HCQ), pharmacy, sarilumab, tocilizumab

The COVID-19 Pandemic: What You Should Know

April 20, 2020 • By Jason Liebowitz, MD

Two rheumatologists offer advice on patient management during the COVID-19 pandemic.... [Read More]

Filed Under: Conditions, Guidelines Tagged With: COVID-19

New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP

April 13, 2020 • By Susan Bernstein

How are COVID-19 and physical distancing restrictions at work affecting rheumatology professionals? The Rheumatologist interviewed clinical pharmacist Wendy Ramey, BSPharm, RPh, CSP, to discuss how the pandemic has changed the way her staff supports rheumatologists at the University of Kentucky Specialty Pharmacy and Infusion Services, Lexington. Ms. Ramey describes how these unprecedented times affect patients,… [Read More]

Filed Under: Practice Management Tagged With: coronavirus, COVID-19, Hydroxychloroquine (HCQ), Medication, pharmacist, sarilumab, Technology, telemedicine, tocilizumab

Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks

April 10, 2020 • By Michael Erman & Axel Threlfall

(Reuters)—Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron’s chief scientific officer told Reuters. “We could be one to two weeks—at most a month or so—away from knowing… [Read More]

Filed Under: Drug Updates Tagged With: COVID-19, sarilumab

Sanofi Can Produce Millions of Doses of HCQ, Potential Coronavirus Drug

April 3, 2020 • By Matthias Blamont & Michael Erman

PARIS (Reuters)—Sanofi SA will be able to provide millions of doses of hydroxychloroquine (HCQ) for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, its chief executive tells Reuters on Thursday. Paul Hudson, who became CEO of the French drugmaker in September, said in an… [Read More]

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, HCQ, Hydroxychloroquine (HCQ), Sanofi

Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

March 31, 2020 • By Reuters Staff

(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada… [Read More]

Filed Under: Drug Updates Tagged With: clinical trials, COVID-19, Regeneron Pharmaceuticals Inc., Sanofi, sarilumab

Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients

March 27, 2020 • By Susan Bernstein

After a study investigated if hydroxycholoroquine (HCQ) benefits COVID-19 patients, the drug—used to treat SLE and RA patients—began running out in pharmacies around the U.S. ACR leaders have asked the FDA to increase monitoring of the HCQ supply…... [Read More]

Filed Under: Drug Updates Tagged With: coronavirus, COVID-19, Drug shortage, HCQ, Hydroxychloroquine (HCQ)

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)